Medium materiality5/10
Raymond James Downgrades Evommune Inc (EVMN) to Outperform
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James upgrades Evommune Inc (EVMN) to Outperform. Target $32. Current price $33.54. Analyst: Martin Auster.
- Raymond James upgrades Evommune to Outperform
- Target $32; Current price $33.54
- Analyst: Martin Auster, Raymond James
Key facts
- 01
Target: $32
- 02
Posted price: $33.54
- 03
Analyst firm: Raymond James
- 04
Analyst: Martin Auster
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.